Randy Teel Biography and Net Worth

CEO of Arvinas

Dr. Randy Teel serves as Arvinas President and Chief Executive Officer, as well as a member of the Company’s Board of Directors. He brings deep experience across corporate strategy, business development, and leadership in the biopharmaceutical industry. Prior to this role he served as Arvinas’ Chief Business Officer, overseeing corporate strategy, business development, investor relations, and communications, and played a key role in shaping the company’s long-term growth strategy, as well as instrumental roles in partnering and capital raising.

Before joining Arvinas, Dr. Teel was Vice President and Head of Strategy at Alexion Pharmaceuticals, where he led long-range planning and partnered closely with R&D and commercial organizations on inline and lifecycle management strategies. He also led enterprise risk management and numerous strategic initiatives across the company. Earlier in his career, Dr. Teel was an Associate Partner at McKinsey & Company, advising biopharmaceutical clients on commercial, medical, and operational strategy.

Dr. Teel holds a B.Sc. in Biology from Gonzaga University and a Ph.D. in Immunobiology from Yale University.

What is Randy Teel's net worth?: The estimated net worth of Randy Teel is at least $2.07 million as of February 23rd, 2026. Teel owns 149,696 shares of Arvinas stock worth more than $2,070,296 as of March 10th. This net worth evaluation does not reflect any other investments that Teel may own. Learn More about Randy Teel's net worth.
How old is Randy Teel?: Teel is currently 44 years old. There are 8 older executives and no younger executives at Arvinas. The oldest executive at Arvinas is Dr. John A. Grosso Ph.D., Senior Vice President of R&D Technical Operations, who is 67 years old. Learn More on Randy Teel's age.
How do I contact Randy Teel?: The corporate mailing address for Teel and other Arvinas executives is 5 SCIENCE PARK 395 WINCHESTER AVE, NEW HAVEN CT, 06511. Arvinas can also be reached via phone at (203) 535-1456 and via email at [email protected]. Learn More on Randy Teel's contact information.
Has Randy Teel been buying or selling shares of Arvinas?: During the past quarter, Randy Teel has sold $110,549.43 of Arvinas stock. Most recently, Randy Teel sold 4,786 shares of the business's stock in a transaction on Monday, February 23rd. The shares were sold at an average price of $12.16, for a transaction totalling $58,197.76. Following the completion of the sale, the chief executive officer now directly owns 149,696 shares of the company's stock, valued at $1,820,303.36. Learn More on Randy Teel's trading history.
Who are Arvinas' active insiders?: Arvinas' insider roster includes Noah Berkowitz (Chief Medical Officer), Sean Cassidy (CFO), John Houston (CEO), David Loomis (CAO), Bradley Margus (Director), Briggs Morrison (Director), Ronald Peck (Insider), Liam Ratcliffe (Director), Andrew Saik (Chief Financial Officer and Treasurer), Timothy Shannon (Director), Ian Taylor (Insider), and Randy Teel (CEO). Learn More on Arvinas' active insiders.
Are insiders buying or selling shares of Arvinas?: In the last year, Arvinas insiders bought shares 2 times. They purchased a total of 50,000 shares worth more than $495,100.00. In the last year, insiders at the sold shares 10 times. They sold a total of 72,017 shares worth more than $851,038.15. The most recent insider tranaction occured on March, 6th when Director Briggs Morrison bought 20,000 shares worth more than $268,000.00. Insiders at Arvinas own 4.7% of the company. Learn More about insider trades at Arvinas.
Information on this page was last updated on 3/6/2026.

Randy Teel Insider Trading History at Arvinas

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
2/23/2026	Sell	4,786	$12.16	$58,197.76	149,696
2/13/2026	Sell	4,403	$11.89	$52,351.67	154,482

Randy Teel Buying and Selling Activity at Arvinas

Arvinas Company Overview

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.

Today's Range

Now: $13.83

$13.75

$14.51

50 Day Range

MA: $12.69

$11.17

$13.83

2 Week Range

Now: $13.83

$5.90

$14.51

Volume

741,504 shs

Average Volume

846,313 shs

Market Capitalization

$884.57 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.87

Randy Teel Biography and Net Worth

What is Randy Teel's net worth?

How old is Randy Teel?

How do I contact Randy Teel?

Has Randy Teel been buying or selling shares of Arvinas?

Who are Arvinas' active insiders?

Are insiders buying or selling shares of Arvinas?